- Home
- SOWG vs INTS Comparison
SOWG vs INTS Comparison
Compare SOWG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- INTS
- Stock Information
- Founded
- SOWG 2010
- INTS 2012
- Country
- SOWG United States
- INTS United States
- Employees
- SOWG N/A
- INTS N/A
- Industry
- SOWG Packaged Foods
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- INTS Health Care
- Exchange
- SOWG Nasdaq
- INTS Nasdaq
- Market Cap
- SOWG 9.3M
- INTS 8.4M
- IPO Year
- SOWG N/A
- INTS 2023
- Fundamental
- Price
- SOWG $0.87
- INTS $0.24
- Analyst Decision
- SOWG
- INTS Strong Buy
- Analyst Count
- SOWG 0
- INTS 2
- Target Price
- SOWG N/A
- INTS $6.75
- AVG Volume (30 Days)
- SOWG 4.4M
- INTS 6.2M
- Earning Date
- SOWG 08-13-2025
- INTS 08-11-2025
- Dividend Yield
- SOWG N/A
- INTS N/A
- EPS Growth
- SOWG N/A
- INTS N/A
- EPS
- SOWG N/A
- INTS N/A
- Revenue
- SOWG $23,063,113.00
- INTS N/A
- Revenue This Year
- SOWG $6.81
- INTS N/A
- Revenue Next Year
- SOWG N/A
- INTS N/A
- P/E Ratio
- SOWG N/A
- INTS N/A
- Revenue Growth
- SOWG N/A
- INTS N/A
- 52 Week Low
- SOWG $0.52
- INTS $0.19
- 52 Week High
- SOWG $20.69
- INTS $4.94
- Technical
- Relative Strength Index (RSI)
- SOWG 47.63
- INTS 30.38
- Support Level
- SOWG $0.77
- INTS $0.32
- Resistance Level
- SOWG $2.12
- INTS $0.36
- Average True Range (ATR)
- SOWG 0.20
- INTS 0.03
- MACD
- SOWG -0.01
- INTS -0.00
- Stochastic Oscillator
- SOWG 7.66
- INTS 30.74
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.